Residual risk reduction opportunities in patients with chronic coronary syndrome. Role of dual pathway inhibition
- 2 July 2020
- journal article
- other
- Published by Taylor & Francis in Expert Review of Clinical Pharmacology
- Vol. 13 (7) , 695-706
Abstract
In this review, the role of the rivaroxaban-plus-aspirin approach (dual pathway inhibition – DPI) in patients with chronic coronary syndrome (CCS) and to perform practical recommendations about its...Keywords
Funding Information
- Bayer Hispania
This publication has 77 references indexed in Scilit:
- Vorapaxar in the Secondary Prevention of Atherothrombotic EventsNew England Journal of Medicine, 2012
- Myocardial Ischemic Events in Patients With Atrial Fibrillation Treated With Dabigatran or Warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) TrialCirculation, 2012
- Rivaroxaban in Patients with a Recent Acute Coronary SyndromeNew England Journal of Medicine, 2012
- The Impact of the Aging Population on Coronary Heart Disease in the United StatesThe American Journal of Medicine, 2011
- Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trialEuropean Heart Journal, 2011
- Three-year follow-up and event rates in the international REduction of Atherothrombosis for Continued Health RegistryEuropean Heart Journal, 2009
- Impact of Proteinuria and Glomerular Filtration Rate on Risk of Thromboembolism in Atrial FibrillationCirculation, 2009
- Explaining the Decrease in U.S. Deaths from Coronary Disease, 1980–2000New England Journal of Medicine, 2007
- The Impact of Renal Dysfunction on Outcomes in the ExTRACT-TIMI 25 TrialJACC, 2007
- Patients With Prior Myocardial Infarction, Stroke, or Symptomatic Peripheral Arterial Disease in the CHARISMA TrialJACC, 2007